Uflex Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Industrial Products | Market Cap: ₹4.4K Cr
Revenue growth driven by volume increases: Q1 FY26 saw a 6.5% revenue increase to approx. UFlex expects new investments (Aseptic Packaging, WPP bags, Recycling facility) to add approx.
From Uflex's Q1 FY26 earnings-call transcript · updated 26 Aug 2026.
Price
₹606
Market Cap
₹4.4K Cr
P/E Ratio
6.4
How does Uflex rank in Industrial Products?
Compare Uflex against every Industrial Products company this quarter on revenue, margins and earnings-call signals.
Uflex — Quarterly revenue & net profit
Revenue Net Profit
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Reported quarterly figures (₹ Cr). Latest: revenue ₹3.6K Cr, net profit ₹36 Cr.
Full financials →📊 Revenue & Sales Performance
- →Revenue growth driven by volume increases: Q1 FY26 saw a 6.5% revenue increase to approx. Rs. 3,922 crores, with packaging volumes up 11.7% YoY and packaging films up 6.8% YoY.
- →Film division volume guidance: Around 132,000 tons per quarter expected for FY26.
- →Asepto packaging volumes: Revised guidance to 8.5-9 billion packs in FY26 (down from 10 billion packs earlier).
- →Capacity utilizations stable with some regional fluctuations; overall volumes expected to consolidate and grow as new capacity comes online.
- →Planned CAPEX of ~Rs. 2,000 crores aiming to add Rs. 3,000 crores in top line and Rs. 600 crores EBITDA at peak utilization.
- →Recycling and virgin PET chip business expected to grow gradually as regulations strengthen.
- →Improved market dynamics post-incident affecting a competitor, leading to better margins and pricing power in India and export markets.
📈 Profitability & Margins
- →UFlex expects new investments (Aseptic Packaging, WPP bags, Recycling facility) to add approx. Rs. 3,000 crores in revenues at 85% capacity utilization.
- →These investments are projected to generate about Rs. 600 crores in EBITDA.
- →The company anticipates better margins in India post a large competitor's accident, with improved pricing power due to reduced exports, especially in Europe.
- →EBITDA margin for the quarter was 12%, slightly lower than the previous year's 12.7%, but expected to improve with new investments.
- →Debt-to-EBITDA ratio may temporarily rise to around 4.1 due to CAPEX but is expected to reduce to about 3 as new projects commission and generate revenue.
- →Market dynamics like US tariff policies and demand shifts are key variables affecting profitability.
- →Overall, with commissioning of new capacities expected in FY26 and FY27, earnings and margins are forecasted to grow sustainably.
🏗️ Capital Expenditure Plans
- →Total planned CAPEX: ~Rs. 2,000 crores, with Rs. 1,100 crores already spent as of June 30, 2025; balance Rs. 900 crores expected in current year and Q1 FY27.
- →Major projects:
- → - Aseptic Packaging greenfield expansion in Egypt (12 billion packs capacity), likely commissioned in FY26.
- → - WPP bags production plant for pet food industry, at an advanced commissioning stage.
- → - Recycling facility in Noida to support government rules on recycled content (30% in rigid, 10% in flexible packaging).
- → - Debottlenecking at Sanand plant.
- →Expected benefits:
- → - Additional revenue potential of Rs. 3,000 crores at ~85% capacity utilization.
- → - Incremental EBITDA of about Rs. 600 crores.
- →CAPEX interest will be capitalized; net debt-to-EBITDA expected to peak around 4.1 before reducing with project ramp-up.
💰 Fundraising & Capital Structure
- →The company has ongoing CAPEX of about Rs. 2,000 crores, with Rs. 1,100 crores already spent as of June 30, 2025, and the remaining Rs. 900 crores expected to be spent during the current year and Q1 FY27.
- →To support these projects, the company has drawn loans, which will increase the net debt-to-EBITDA ratio slightly, estimated to peak at around 4.0-4.1 in the near term.
- →Interest on borrowings for these projects is capitalized, so it has no immediate impact on P&L.
- →There is no explicit mention of any future equity fundraising or additional debt beyond what is needed for the current CAPEX.
- →Debt is expected to reduce after the projects commission and profits kick in, with a plan to get the net debt-to-EBITDA ratio below 3 in the medium term.
📋 Order Book & Pipeline
The transcript does not explicitly mention the current or expected order book or pending orders details for UFLEX Limited. However, some relevant points that indirectly relate to order and demand status are:
- Post May 2025 fire incident at a competitor's plant, Indian exports of films to Europe have decreased, potentially reducing order inflow from India to Europe.
- North American market demand remained muted in Q1 FY26 due to tariff uncertainties, causing customer hesitation in order placements.
- Nigeria underperformed in Q1 FY26 due to US tariffs, impacting capacity utilization and order volumes temporarily.
- Overall, volume growth of 7.9% year-on-year was recorded, driven by packaging films growing 6.8% in Q1 FY26.
- Expected stabilization and better pricing power in coming quarters as tariff and import situations get settled.
- Aseptic packaging capacity expansion is slightly delayed; volumes for FY26 expected around 8.5-9 billion packs versus initial guidance of 10 billion packs.
No direct numerical orderbook or backlog figures were disclosed.
Key Metrics
Frequently Asked Questions
What were Uflex Q1 FY26 results?
Revenue growth driven by volume increases: Q1 FY26 saw a 6.5% revenue increase to approx. UFlex expects new investments (Aseptic Packaging, WPP bags, Recycling facility) to add approx.
What is Uflex share price analysis?
Uflex currently shows a neutral. The stock trades at a P/E of 6.4 with a market cap of ₹4,438 Cr. Investors should review the full earnings analysis for detailed insights.
Is Uflex planning capital expenditure?
Total planned CAPEX: ~Rs.
Keep Uflex on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.